These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19287043)

  • 1. Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested.
    Zhang X; Silkey M; Schumacher M; Wang L; Raval H; Caulfield JP
    J Clin Pharmacol; 2009 May; 49(5):534-9. PubMed ID: 19287043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
    Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
    Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.
    Holzgrefe HH; Cavero I; Buchanan LV; Gill MW; Durham SK
    J Pharmacol Toxicol Methods; 2007; 55(3):227-37. PubMed ID: 17097307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.
    Davis JD; Hackman F; Layton G; Higgins T; Sudworth D; Weissgerber G
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):68-75. PubMed ID: 18333868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
    Zhang L; Chappell J; Gonzales CR; Small D; Knadler MP; Callaghan JT; Francis JL; Desaiah D; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Derby M
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):146-53. PubMed ID: 17414226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical characteristics of moxifloxacin-induced QTc effect.
    Yan LK; Zhang J; Ng MJ; Dang Q
    J Biopharm Stat; 2010 May; 20(3):497-507. PubMed ID: 20358432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Malhotra BK; Glue P; Sweeney K; Anziano R; Mancuso J; Wicker P
    Clin Pharmacol Ther; 2007 Mar; 81(3):377-85. PubMed ID: 17339867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of vardenafil and sildenafil on cardiac repolarization.
    Morganroth J; Ilson BE; Shaddinger BC; Dabiri GA; Patel BR; Boyle DA; Sethuraman VS; Montague TH
    Am J Cardiol; 2004 Jun; 93(11):1378-83, A6. PubMed ID: 15165918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
    Kori S; Kellerman DJ; Voloshko P; Haugen G
    Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers.
    Taubel J; Naseem A; Harada T; Wang D; Arezina R; Lorch U; Camm AJ
    Br J Clin Pharmacol; 2010 Apr; 69(4):391-400. PubMed ID: 20406223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.
    Hug B; Abbas R; Leister C; Burns J; Sonnichsen D
    Clin Cancer Res; 2010 Aug; 16(15):4016-23. PubMed ID: 20647478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.
    Démolis JL; Kubitza D; Tennezé L; Funck-Brentano C
    Clin Pharmacol Ther; 2000 Dec; 68(6):658-66. PubMed ID: 11180026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
    Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
    Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
    Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
    Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies.
    Mason JW; Florian JA; Garnett CE; Moon TE; Selness DS; Spaulding RR
    J Clin Pharmacol; 2010 Nov; 50(11):1249-59. PubMed ID: 20145260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrocardiographic QTc changes due to moxifloxacin infusion.
    Malik M; Hnatkova K; Schmidt A; Smetana P
    J Clin Pharmacol; 2009 Jun; 49(6):674-83. PubMed ID: 19451404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
    Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
    J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.
    Sarapa N; Nickens DJ; Raber SR; Reynolds RR; Amantea MA
    Clin Pharmacol Ther; 2008 Jan; 83(1):153-9. PubMed ID: 17581594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.